#AsahiIntecc

Asahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan for the embolic agent "Nexsphere-F™" from Korea's NEXTBIOMEDICAL on April 9, 2026. The contract period is five years following insurance listing, with no impact on consolidated results for the current fiscal year.

Asahi Intecc has published the “Integrated Report 2025,” disclosing initiatives to enhance corporate value including ESG, centered on the new medium-term management plan.